[VIRTUAL] SECONDARY QUALITY-OF-LIFE DOMAINS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH THE BCMA-DIRECTED CAR T CELL THERAPY IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121): RESULTS FROM THE KARMMA CLINICAL TRIAL

[VIRTUAL] CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

[VIRTUAL] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS INELIGIBLE FOR TRANSPLANTATION: FRAILTY SUBGROUP ANALYSIS OF ALCYONE

[VIRTUAL] DARATUMUMAB PLUS LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF GRIFFIN AFTER 12 MONTHS OF MAINTENANCE THERAPY

[VIRTUAL] PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), BCMA-DIRECTED CAR-T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

[VIRTUAL] REAL-WORLD EFFICACY AND TOLERABILITY OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM ANALYSIS OF THE REMIX STUDY

[VIRTUAL] TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM AN ONGOING PHASE 1 STUDY

[VIRTUAL] TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS

[VIRTUAL] UPDATED ANALYSIS OF DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE-NDMM): THE PHASE 3 MAIA STUDY

[VIRTUAL] DARATUMUMAB SC + SOC IN MM ACROSS LINES OF THERAPY IN PHASE-2 PLEIADES: INITIAL RESULTS FOR DARATUMUMAB SC + CARFILZOMIB/DEXAMETHASONE AND UPDATED RESULTS FOR DARATUMUMAB SC + BORTEZOMIB/MELPHALAN/PREDNISONE OR LENALIDOMIDE/DEXAMETHASONE

[VIRTUAL] DREAMM-2 (NCT03525678): SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) EFFECTS ON PATIENT-REPORTED OUTCOME (PRO) MEASURES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

[VIRTUAL] CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN THE PHASE 1B/2 CARTITUDE-1 STUDY

[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN 55 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH EXTRAMEDULLARY DISEASE (EMD)—SUBGROUP ANALYSIS

[VIRTUAL] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA HIGH-RISK SUBGROUP ANALYSES